Single User License
INR 136740
Site License
INR 273480
Corporate User License
INR 410220

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


High-Grade Glioma-Pipeline Review, H1 2015

High-Grade Glioma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

High-Grade Glioma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'High-Grade Glioma-Pipeline Review, H1 2015', provides an overview of the High-Grade Glioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for High-Grade Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High-Grade Glioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of High-Grade Glioma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for High-Grade Glioma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the High-Grade Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the High-Grade Glioma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for High-Grade Glioma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding High-Grade Glioma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

High-Grade Glioma Overview 8

Therapeutics Development 9

Pipeline Products for High-Grade Glioma-Overview 9

Pipeline Products for High-Grade Glioma-Comparative Analysis 10

High-Grade Glioma-Therapeutics under Development by Companies 11

High-Grade Glioma-Therapeutics under Investigation by Universities/Institutes 13

High-Grade Glioma-Pipeline Products Glance 14

Clinical Stage Products 14

Early Stage Products 15

High-Grade Glioma-Products under Development by Companies 16

High-Grade Glioma-Products under Investigation by Universities/Institutes 17

High-Grade Glioma-Companies Involved in Therapeutics Development 18

AngioChem Inc. 18

Bayer AG 19

Boehringer Ingelheim GmbH 20

Cavion LLC 21

GlaxoSmithKline plc 22

Kinex Pharmaceuticals, LLC 23

Millennium Pharmaceuticals, Inc. 24

Oncolytics Biotech Inc. 25

Sanofi 26

Stemline Therapeutics, Inc. 27

Targepeutics, Inc. 28

Tocagen Inc. 29

Virttu Biologics Limited 30

High-Grade Glioma-Therapeutics Assessment 31

Assessment by Monotherapy Products 31

Assessment by Combination Products 32

Assessment by Target 33

Assessment by Mechanism of Action 35

Assessment by Route of Administration 37

Assessment by Molecule Type 39

Drug Profiles 41

(dabrafenib mesylate + trametinib dimethyl sulfoxide)-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

alisertib-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

ANG-1005-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

crenolanib besylate-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Dendritic Cell Therapy for Gliomas-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Dendritic Cell Therapy for Oncology-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

GB-13-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Gene Therapy for High-Grade Glioma and Liver Transplantation-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

HSV-1716-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

KX-02-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

mibefradil dihydrochloride-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

nintedanib-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

pelareorep-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

plerixafor-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

SL-701-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

sorafenib tosylate-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Stem Cell Therapy for Glioma-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

TBX-01-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Toca-Gamma-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Toca-RNAi-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

vocimagene amiretrorepvec + flucytosine ER-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

High-Grade Glioma-Recent Pipeline Updates 85

High-Grade Glioma-Dormant Projects 115

High-Grade Glioma-Discontinued Products 116

Appendix 117

Methodology 117

Coverage 117

Secondary Research 117

Primary Research 117

Expert Panel Validation 117

Contact Us 117

Disclaimer 118

List of Tables

Number of Products under Development for High-Grade Glioma, H1 2015 9

Number of Products under Development for High-Grade Glioma-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Investigation by Universities/Institutes, H1 2015 17

High-Grade Glioma-Pipeline by AngioChem Inc., H1 2015 18

High-Grade Glioma-Pipeline by Bayer AG, H1 2015 19

High-Grade Glioma-Pipeline by Boehringer Ingelheim GmbH, H1 2015 20

High-Grade Glioma-Pipeline by Cavion LLC, H1 2015 21

High-Grade Glioma-Pipeline by GlaxoSmithKline plc, H1 2015 22

High-Grade Glioma-Pipeline by Kinex Pharmaceuticals, LLC, H1 2015 23

High-Grade Glioma-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 24

High-Grade Glioma-Pipeline by Oncolytics Biotech Inc., H1 2015 25

High-Grade Glioma-Pipeline by Sanofi, H1 2015 26

High-Grade Glioma-Pipeline by Stemline Therapeutics, Inc., H1 2015 27

High-Grade Glioma-Pipeline by Targepeutics, Inc., H1 2015 28

High-Grade Glioma-Pipeline by Tocagen Inc., H1 2015 29

High-Grade Glioma-Pipeline by Virttu Biologics Limited, H1 2015 30

Assessment by Monotherapy Products, H1 2015 31

Assessment by Combination Products, H1 2015 32

Number of Products by Stage and Target, H1 2015 34

Number of Products by Stage and Mechanism of Action, H1 2015 36

Number of Products by Stage and Route of Administration, H1 2015 38

Number of Products by Stage and Molecule Type, H1 2015 40

High-Grade Glioma Therapeutics-Recent Pipeline Updates, H1 2015 85

High-Grade Glioma-Dormant Projects, H1 2015 115

High-Grade Glioma-Discontinued Products, H1 2015 116

List of Figures

Number of Products under Development for High-Grade Glioma, H1 2015 9

Number of Products under Development for High-Grade Glioma-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Assessment by Monotherapy Products, H1 2015 31

Assessment by Combination Products, H1 2015 32

Number of Products by Top 10 Targets, H1 2015 33

Number of Products by Stage and Top 10 Targets, H1 2015 33

Number of Products by Top 10 Mechanism of Actions, H1 2015 35

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 35

Number of Products by Top 10 Routes of Administration, H1 2015 37

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 38

Number of Products by Top 10 Molecule Types, H1 2015 39

Number of Products by Stage and Top 10 Molecule Types, H1 2015 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AngioChem Inc.

Bayer AG

Boehringer Ingelheim GmbH

Cavion LLC

GlaxoSmithKline plc

Kinex Pharmaceuticals, LLC

Millennium Pharmaceuticals, Inc.

Oncolytics Biotech Inc.

Sanofi

Stemline Therapeutics, Inc.

Targepeutics, Inc.

Tocagen Inc.

Virttu Biologics Limited

High-Grade Glioma Therapeutic Products under Development, Key Players in High-Grade Glioma Therapeutics, High-Grade Glioma Pipeline Overview, High-Grade Glioma Pipeline, High-Grade Glioma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com